Key Takeaways
- Formulation-led margin recovery: Gross margin improved sharply as the higher-margin formulation business grew ~14% domestic and ~23% branded exports, while lower-margin API declined ~23%, creating a favorable mix shift that management calls sustainable.
- API business hit by dual headwinds: Antimalarial API demand collapsed and sartan KSM prices fell from $18-$20 to ~$6.5, dragging Losartan API prices from $100-$120 to $55-$60; management expects KSM prices to recover within 6 months as manufacturers are losing money at current levels.
- Unichem acquisition on track, integration pending: The open offer closes around 8th September with management control by September-end; ground-level consolidation and financial consolidation will only begin from Q3, and management declined to quantify the near-term P&L drag.
- US FDA resolution progressing, timeline uncertain: All three sites inspected with no repeat observations and no data integrity issues; Ratlam inspection closed mid-June, but management cautioned that import alert lifting may take time and would not commit to a business restart date.
- What to watch next quarter: Whether KSM prices actually bottom and begin recovering, the pace of Unichem integration and its financial impact once consolidated, and any progress on US FDA import alert resolution.
Domestic & Branded Formulation Momentum
- Broad-based domestic growth: Domestic formulations grew ~14%, with pain management, CNS, derma, urology and ophthalmology all delivering strong performance; only antibacterials were weak at ~5%.
- Field force investments turning productive: New divisions in rheumatoid arthritis, cardiovascular and CNS reached breakeven in their first year; one cardiovascular division may take one more year; the pain/Zerodol division added ~300 people and is showing good traction.
- Branded export strength: Branded formulation exports grew ~23% in Q1, with Europe including the UK surging 63% (Rs. 73 cr to Rs. 119 cr); the UK alone may deliver Rs. 130-Rs. 140 cr for the full year versus Rs. 64 cr last year.
- Generic formulation exports on track: Grew 11% in Q1 against guidance of 7%-8%, though institutional generics were impacted by lower antimalarial WHO-qualified formulation business; good orders are now coming in.
A. K. Jain: "practically the KSM manufacturers are losing money now at that level. So, it is not that these things will continue for very long, maybe matter of 6 months, the KSM prices will again start rising."
API Headwinds & KSM Price Collapse
- Antimalarial API demand collapse: The institutional antimalarial business declined significantly due to lower procurement by global agencies and a plant shutdown for sterile Artesunate API section upgradation; lower volumes came from Artemether, Lumefantrine, Artesunate and Amodiaquine formulations.
- Sartan pricing driven by import-side KSM decline: Sartan starting material prices fell from $18-$20 to ~$6.5, pushing Losartan API prices from $100-$120 to $55-$60; even with similar volumes, revenues are declining, and domestic producers must match import prices to stay in business.
- Sartan impurity issues resolved industry-wide: Nitrosamine and Azido impurity challenges have been addressed over the last 1.5-2 years; regulators have issued further guidelines and Ipca does not foresee any reason its APIs would not meet them. A lower-cost sartan process has been filed, though some market approvals in LATAM and Brazil are still pending.
- Sterile Artesunate upgrade completed: The sterile Artesunate API section upgrade is done, the product is validated and data has been filed with WHO; approval is expected in ~1 month, after which injectable shipments will resume, though August and September may still be impacted.
Margin Walk & Cost Drivers
- Gross margin improvement is structural: The improvement came from formulation business growth, lower input costs, a favorable mix shift as lower-margin API declined, and cost optimization on the API side; management stated this is sustainable.
- Freight and energy costs normalized: Freight costs have normalized and energy costs have stabilized; manufacturing and other expenses moved only ~3%.
- Material cost ratio improving sharply: Material cost to sales is guided to ~31.5%-32% for FY24, an improvement of ~3.5%-4% versus the prior year.
- Subsidiary drag shrinking: The drag from subsidiaries Onyx and Pisgah was around Rs. 3.5 crore at the PAT level in Q1 and is already coming down.
- Management declined to quantify the mix benefit: When asked to break out how much of the margin expansion came from product mix versus other factors, management said the working had not been done and may be available by the next quarter call.
Unichem Acquisition & Integration
- Timeline locked: The open offer opens 28th August, closes around 8th September, with payments by ~20th September; management control is expected by September-end, and ground-level actions start only after that, with major consolidation from Q3 onwards.
- US platform strategy shifts to Unichem: Unichem has a much bigger US platform with over 30 people and a strong US business; Ipca intends to use Unichem as its frontend for future US business rather than Bayshore, integrating Bayshore into the Unichem portfolio to achieve operating cost reductions.
- Financial impact undisclosed: Management declined to quantify the drag from Unichem on a PAT or PBT basis from September onwards, stating Unichem is improving its performance and details can only be provided once Ipca is in management.
- Product and team integration work has begun: Work on product market extensions and team interactions has already started even before formal management control.
A. K. Jain: "practically on ground actions will start only after completely we are in the management here."
US FDA & Regulatory Pathway
- All three sites inspected with clean outcomes: No repeat observations and no data integrity issues across all three facilities; the Ratlam inspection was closed in mid-June.
- Import alert timeline remains uncertain: Management hopes to hear from regulators within 90 days of the Ratlam inspection closure, but cautioned that import alert lifting may take time and it would not be right to comment on when business would start.
- US focus likely on formulations, not API: Management indicated the focus is likely to be more on formulations for the US market rather than API.
A. K. Jain: "There are no repeat observations and also there are no kind of data integrity kind of issues. So, hopefully we should get cleared and I think it is only a matter of time..."
Dewas Site & Continuous Process Plant
- Dewas site yet to be inspected: Four products are validated and filed in various markets; further validations are underway. By year-end, some domestic business or small business may come from markets not requiring inspections. European and other authority inspections are expected in H2 FY24, after which business will scale up; the plant will continue to have losses this year.
- Continuous process plant nearing operation: The first continuous process plant has been set up; the first product, Furosemide raw material, will start producing in-house through the continuous process, with 2-3 more candidates in the pipeline. Operations should begin around October or November.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic formulation growth | ~12% to 14% growth | FY24 |
| Branded export formulation growth | ~12% to 14% growth (lower due to currency depreciation) | FY24 |
| Generic formulation export growth | ~7% to 8% growth | FY24 |
| Institutional antimalarial decline | ~15% decline | FY24 |
| API business decline | ~10% to 12% decline | FY24 |
| Overall revenue growth | Single digit to ~6%-8% | FY24 |
| Material cost to sales ratio | ~31.5% to 32% (improvement of ~3.5%-4%) | FY24 |
| EBITDA margin | ~19% to 19.5% (excluding other income) | FY24 |
| API business normalized growth | ~10% to 12% growth | FY25 (next year) |
| KSM price recovery | Prices to start rising again as manufacturers are losing money | ~6 months |
| WHO sterile Artesunate approval | Approval expected, injectable shipments to resume thereafter | ~1 month |
| Unichem management control | Open offer closes, payments made, control obtained | September-end |
| Unichem major consolidation | Financial and operational consolidation begins | Q3 FY24 onwards |
| Dewas site inspections | European and other authority inspections begin | H2 FY24 |
| Continuous process plant start | Furosemide production begins via continuous process | October-November |
| One cardiovascular division breakeven | Division reaches breakeven | Next financial year |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Domestic formulation growth | ~14% YoY |
| Domestic formulation growth vs industry | ~13% for Ipca vs ~11% for industry as per IQVIA |
| Export branded formulation revenue | ~₹114 cr, up ~23% YoY from ₹93 cr |
| Generic formulation revenue (excl. institutional) | ~₹235 cr, up 11% YoY from ₹212 cr |
| Institutional antimalarial revenue | ₹48 cr, down from ₹97 cr YoY |
| API revenue | ₹295 cr, down ~23% YoY from ₹384 cr |
| Antimalarial API revenue | ₹19 cr, down from ₹63 cr YoY, a decline of ~₹44 cr |
| Standalone profit after tax | ₹166.58 cr |
| Consolidated profit after tax | ₹162.82 cr, drag from subsidiaries of ~₹3.76 cr |
| EBITDA margin (standalone, excl. other income) | 16.26% in FY23, guidance of ~19% to 19.5% for FY24 |
| Material cost to sales ratio | Expected to improve from ~35.5% in FY23 to ~31.5%–32% in FY24 |
| Overall revenue growth guidance for FY24 | ~6% to 8% |
| Field force size | ~6,180 people |
| Monthly field force productivity | ~₹4.22 lakhs, up from ₹4.08 lakhs YoY |
| Europe (incl. UK) formulation revenue | ~₹119 cr, up ~63% YoY from ₹73 cr |
| CAPEX guidance for FY24 | ~₹300 cr |